FDA expands list of valsartan recalls
pharmafile | August 9, 2018 | News story | Medical Communications | China, FDA, US, heart medication, recall, valsartan
The US Food and Drug Administration (FDA) has expanded a list of products containing valsartan that are to be recalled.
The FDA announced an initial recall of drugs containing valsartan, which is used to treat high blood pressure and heart failure, in July of this year after it was discovered that some drugs could have been contaminated with carcinogenic substances. The drug had previously been recalled in 22 countries.
Drugs containing valsartan were found to have tested positive for N-nitrosodimethylamine (NMDA) which is considered a possible carcinogen by the U.S. Environmental Protection Agency. The contaminant is often a byproduct in certain manufacturing processes.
The FDA said in a statement that they are “working with drug manufacturers to ensure future valsartan active pharmaceutical ingredients (APIs) are not at risk of NDMA formation.”
It was further noted that “The agency reminds manufacturers to thoroughly evaluate their API manufacturing processes, and changes to those processes, to detect any unsafe impurities. If a manufacturer detects new or higher levels of impurity, they should take action to prevent changes to the product’s safety profile.”
The recalled medicines have been linked to manufacturing facilities in the Zhejiang province in the east of China. The contaminated medicines were supplied by Zhejiang Huahai Pharmaceuticals who noted that they informed authorities as soon as they identified the impurity.
“We published our recall notice at midday on July 13 in China and overseas, and published the U.S. market recall notice on July 14 Beijing time … all the drug materials for the Chinese market were recalled by July 23,” the company said in a statement to the Shanghai stock exchange last month.
Louis Goss
Related Content
EndoCyclic New Drug application approved by US FDA for endometriosis treatment
EndoCyclic Therapeutics’ Investigational New Drug (IND) application for its lead programme, ENDO-205, has been approved …
Coriolis Pharma opens new US headquarter and laboratory
Coriolis Pharma has opened a new US headquarter and laboratory at the Alexandria Center for …
Abselion establishes a US subsidiary in Massachusetts
Abselion has established a US subsidiary at The Engine in Cambridge, Massachusetts in the US. …
